United Kingdom Transthyretin Amyloidosis Therapeutics Market 2023 Is Ready to Set Outstanding Growth in Upcoming Years

Report Overview

The UK Transthyretin Amyloidosis (ATTR) Therapeutics market size stood at around USD 0.012 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Transthyretin Amyloidosis (ATTR) is caused by the transthyretin (TTR) protein and occurs in two forms, either hereditary or wild type. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. The United Kingdom has the lowest prevalent population in 2016.

Till 2019, 711 patients with wild-type ATTR-CM, 205 with hereditary ATTR-CM associated with the V122I variant (V122I-hATTR-CM), and 118 with non-V122I-hATTR-CM at the UK National Amyloidosis Centre were studied. Patients with V122I-hATTR-CM were more impaired functionally and had worse measures of cardiac disease at the time of diagnosis, a greater decline in quality of life, and poorer survival in comparison with the other subgroups.

Market Growth Drivers

The growth will be driven by the surge in the development of drug therapies of varying mechanisms, and the overall rise in diagnosed patient population due to a much-needed increase in awareness and understanding of the disease among clinicians and the public.

The main driver of the ATTR market expansion will be the approval and launch of the RNA interference therapeutics for both ATTR polyneuropathy and ATTR cardiomyopathy. Another prominent contributor to sales growth is the increase in diagnosed prevalence, the increase will be caused by improved understanding and awareness of the disease alongside campaigns by drug developers to increase genetic testing.

The ATTR market currently has unlimited competition and holds room for new entrants.

The key market opportunities lie in addressing unmet needs through the development of efficacious therapies for clearing already deposited amyloid and increasing the number of therapies approved for ATTR cardiomyopathy.

Market Restraints

The major barrier for the ATTR market will be the huge annual cost of therapy for new pipeline drugs and the lack of options for advanced disease states, the stage at which the majority of patients are diagnosed.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/139895/

Top Major Players

Many new players are emerging in the transthyretin amyloidosis (ATTR) therapeutics market, as a result of a number of growth opportunities. Some of the major key players prominent in the market are Pfizer Inc, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics.

Patisiran and Inotersen sold under the brand name ONPATTRO and TEGSEDI marketed by Alnylam Pharmaceuticals and Ionis Pharmaceuticals respectively.

VYNDAQEL (tafamidis), a once-daily 61 mg oral capsule for the treatment of wild type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

The report delivers the challenges in front of the United Kingdom Transthyretin Amyloidosis Therapeutics Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the United Kingdom Transthyretin Amyloidosis Therapeuticss Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On United Kingdom Transthyretin Amyloidosis Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139895/

Market Segmentation

By Products Type:

Various kind of drugs and other treatments options available to treat Hereditary ATTR (hATTR) and Wild type ATTR.

Hereditary (Familial) ATTR amyloidosis has an alteration (mutation) in the DNA that can be passed down from generation to generation. As a result, the TTR protein becomes more unstable and prone to forming amyloid fibrils. The most common mutation in the UK is called TTR Thr60Ala (T60A), often seen in people with Irish ancestry. Val122Ile associated hereditary ATTR amyloidosis mainly affects the heart and may also cause carpal tunnel syndrome.

Wild-type ATTR amyloidosis - Wild-type involves no aberrant DNA and cannot be handed down through the generations. Instead, the normal TTR protein becomes unstable as you get older, misfolds, and creates amyloid fibrils.

By Genetic Based Therapies:

On the basis of genetic-based therapies, the ATTR disease therapeutics market can be categorised as

Patisiran

Inotersen

Vutrisiran

AKCEA-TTR-LRx

Others

Regulatory authorities in the UK approved Patisiran (a small interfering RNA drug) and Inotersen (an antisense oligonucleotide drug) for treating neuropathy caused by hereditary ATTR amyloidosis. The APOLLO-B study is evaluating the efficacy and safety of Patisiran in patients with ATTR amyloidosis (hereditary or wild type) with cardiomyopathy. Vutrisiran (AL-YTTRSCO2) is a second-generation RNA inhibitor belonging to the small interfering RNA drug class. AKCEA-TTR-LRx is a second-generation RNA inhibitor, belonging to the antisense oligonucleotide drug class. Out of these, Patisiran and Inotersen, aim to "switch off" the TTR gene in the liver cells, so that TTR (both mutant and wild-type) is simply not produced, hence these two drugs are more often used to treat ATTR in the UK.

By TTR Stabilizer:

AG10 is a new selective TTR stabilizer drug being developed to treat ATTR amyloidosis. The Eidos AG10-301 study is evaluating the efficacy and safety of AG-10 in patients with symptomatic ATTR amyloidosis cardiomyopathy (hereditary and wild type).

By CRISPR/Cas Gene Editing Therapy:

CRISPR/cas9 technology is a novel gene-editing tool that allows scientists to alter genes very precisely and efficiently. NTLA-2001 is the first CRISPR therapy to be administered systemically (intravenously) to edit genes inside the body. NLTA-2001 uses a lipid nanoparticle delivery system to deliver the gene-editing CRISPR protein to the liver.  The goal is to permanently delete the gene for TTR in a single course of treatment.

By Product Application:

As per the product application, the ATTR disease treatment market can be categorised as

Ambulatory and Surgical Centres

Hospitals and Clinics

Diagnostic Centres

Others

Clinical evaluation of patients can usually be completed over 1-2 days during which hospitals or other accommodation can be arranged. Treatment is usually administered at patients' local hospitals or at other regional centres in conjugation with advice form and reviews at the National Amyloidosis Centre. A small proportion of cases are managed directly at the Royal Free Hospital. Most patients with amyloidosis need long term surveillance, with six-monthly or annual specialist follow up in the shorter term.

Top Major Players

Many new players are emerging in the transthyretin amyloidosis (ATTR) therapeutics market, as a result of a number of growth opportunities. Some of the major key players prominent in the market are Pfizer Inc, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics.

Patisiran and Inotersen sold under the brand name ONPATTRO and TEGSEDI marketed by Alnylam Pharmaceuticals and Ionis Pharmaceuticals respectively.

VYNDAQEL (tafamidis), a once-daily 61 mg oral capsule for the treatment of wild type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

The United Kingdom Transthyretin Amyloidosis Therapeutics Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the United Kingdom Transthyretin Amyloidosis Therapeutics market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the United Kingdom Transthyretin Amyloidosis Therapeutics Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic United Kingdom Transthyretin Amyloidosis Therapeutics market. Each section of the research study is specially prepared to explore key aspects of the global United Kingdom Transthyretin Amyloidosis Therapeutics Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global United Kingdom Transthyretin Amyloidosis Therapeutics market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/139895/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global United Kingdom Transthyretin Amyloidosis Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the United Kingdom Transthyretin Amyloidosis Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the United Kingdom Transthyretin Amyloidosis Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the United Kingdom Transthyretin Amyloidosis Therapeutics
Chapter 4: Presenting the United Kingdom Transthyretin Amyloidosis Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the United Kingdom Transthyretin Amyloidosis Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/139895/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.